Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1

5(83.3%)

N/A

1(16.7%)

6Total

Early Phase 1(5)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05127369Not ApplicableUnknown

Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression

Role: lead

NCT04302519Early Phase 1Unknown

Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells

Role: lead

NCT03658655Early Phase 1Completed

Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes

Role: lead

NCT03957655Early Phase 1Unknown

Safety and Efficacy of SHED for Decompensated Liver Cirrhosis

Role: collaborator

NCT04130100Early Phase 1Unknown

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Role: lead

NCT03912480Early Phase 1Unknown

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Role: lead

All 6 trials loaded